Adverse effects on women: abdominal cramps · women in the postpartum period
Vitamin A supplementation (200,000 to 400,000 IU) showed no clear difference in maternal adverse effects after administration: abdominal pain compared with placebo or no treatment (low certainty).
1 finding from 1 review
Maternal breast milk retinol concentration · women in the postpartum period
1 finding from 1 review
Change in Infant Mortality Rate per 1000 live births1 · women in the postpartum period
Vitamin A supplementation (200,000 to 400,000 IU) showed no clear difference in infant mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
Infant morbidity (gastroenteritis) · women in the postpartum period
It is very uncertain whether vitamin A supplementation (200,000 to 400,000 IU) changes infant morbidity (gastroenteritis) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Infant adverse effects: bulging fontanelle · women in the postpartum period
Vitamin A supplementation (200,000 to 400,000 IU) showed no clear difference in infant adverse effects: bulging fontanelle compared with placebo or no treatment (low certainty).
1 finding from 1 review
Caries presence in primary teeth · For interventions, pregnant women, mothers or other caregivers of infants in the first year of life; for outcomes, children up to 6 years…
It is very uncertain whether high-dose vitamin D3 supplementation during pregnancy (2400 IU/day… changes caries presence in primary teeth compared with low-dose (standard) vitamin D supplementation as recommended in… (very low certainty).
1 finding from 1 review
Dental caries · For interventions, pregnant women, mothers or other caregivers of infants in the first year of life; for outcomes, children up to 6 years…
The review found no eligible studies for this question.
2 findings from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in all‐cause mortality (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in symptomatic catheter‐related thrombosis (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no VKA (very low certainty).
1 finding from 1 review
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in major bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in minor bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Antibiotic versus heparin only lock/flush solution: catheter‐related infections · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in catheter‐related infection (3 months) compared with no VKA (low certainty).
1 finding from 1 review
Premature CVC removal (3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in premature CVC removal (3 months) compared with no VKA (low certainty).
1 finding from 1 review